CL2014002979A1 - Una composicion farmaceutica para administracion sublingual que comprende una mezcla de a) microparticulas de alfentanilo, presentandose en las superficies de particulas vehiculo mas grandes, b) una base debil soluble en agua, y c) un compuesto acido debil en mezcla intima con las microparticulas de alfentanilo; su procedimiento de preparacion; y su uso para el tratamiento del dolor. - Google Patents

Una composicion farmaceutica para administracion sublingual que comprende una mezcla de a) microparticulas de alfentanilo, presentandose en las superficies de particulas vehiculo mas grandes, b) una base debil soluble en agua, y c) un compuesto acido debil en mezcla intima con las microparticulas de alfentanilo; su procedimiento de preparacion; y su uso para el tratamiento del dolor.

Info

Publication number
CL2014002979A1
CL2014002979A1 CL2014002979A CL2014002979A CL2014002979A1 CL 2014002979 A1 CL2014002979 A1 CL 2014002979A1 CL 2014002979 A CL2014002979 A CL 2014002979A CL 2014002979 A CL2014002979 A CL 2014002979A CL 2014002979 A1 CL2014002979 A1 CL 2014002979A1
Authority
CL
Chile
Prior art keywords
alfentanil
microparticles
weak
pain
presenting
Prior art date
Application number
CL2014002979A
Other languages
English (en)
Spanish (es)
Inventor
Anders Pettersson
Emil Schwan
Barbro Johansson
Original Assignee
Orexo Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48577134&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014002979(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1207701.2A external-priority patent/GB201207701D0/en
Priority claimed from GBGB1221130.6A external-priority patent/GB201221130D0/en
Application filed by Orexo Ab filed Critical Orexo Ab
Publication of CL2014002979A1 publication Critical patent/CL2014002979A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CL2014002979A 2012-05-02 2014-11-03 Una composicion farmaceutica para administracion sublingual que comprende una mezcla de a) microparticulas de alfentanilo, presentandose en las superficies de particulas vehiculo mas grandes, b) una base debil soluble en agua, y c) un compuesto acido debil en mezcla intima con las microparticulas de alfentanilo; su procedimiento de preparacion; y su uso para el tratamiento del dolor. CL2014002979A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1207701.2A GB201207701D0 (en) 2012-05-02 2012-05-02 New pharmaceutical composition
GBGB1221130.6A GB201221130D0 (en) 2012-11-23 2012-11-23 New pharmaceutical composition

Publications (1)

Publication Number Publication Date
CL2014002979A1 true CL2014002979A1 (es) 2014-12-05

Family

ID=48577134

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014002979A CL2014002979A1 (es) 2012-05-02 2014-11-03 Una composicion farmaceutica para administracion sublingual que comprende una mezcla de a) microparticulas de alfentanilo, presentandose en las superficies de particulas vehiculo mas grandes, b) una base debil soluble en agua, y c) un compuesto acido debil en mezcla intima con las microparticulas de alfentanilo; su procedimiento de preparacion; y su uso para el tratamiento del dolor.

Country Status (33)

Country Link
US (4) US8815911B2 (enExample)
EP (2) EP3150199B1 (enExample)
JP (1) JP6275696B2 (enExample)
KR (1) KR20150005695A (enExample)
CN (1) CN104427978B (enExample)
AU (1) AU2013255640B2 (enExample)
BR (1) BR112014027213A8 (enExample)
CA (1) CA2871805A1 (enExample)
CL (1) CL2014002979A1 (enExample)
CO (1) CO7170181A2 (enExample)
CY (2) CY1118570T1 (enExample)
DK (2) DK2849730T3 (enExample)
EA (1) EA028110B1 (enExample)
ES (2) ES2614757T3 (enExample)
HR (2) HRP20161634T1 (enExample)
HU (1) HUE031792T2 (enExample)
IL (1) IL235272B (enExample)
IN (1) IN2014MN02156A (enExample)
LT (2) LT2849730T (enExample)
ME (1) ME02644B (enExample)
MX (1) MX360665B (enExample)
NZ (1) NZ701428A (enExample)
PE (1) PE20142444A1 (enExample)
PH (1) PH12014502407A1 (enExample)
PL (2) PL2849730T3 (enExample)
PT (2) PT3150199T (enExample)
RS (2) RS55489B1 (enExample)
SG (1) SG11201407081PA (enExample)
SI (2) SI2849730T1 (enExample)
SM (3) SMT201700086T1 (enExample)
TR (1) TR201815935T4 (enExample)
WO (1) WO2013164620A1 (enExample)
ZA (1) ZA201407559B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX361757B (es) 2011-09-19 2018-12-13 Orexo Ab Nueva composicion farmaceutica resistente al abuso para el tratamiento de la dependencia de opioides.
PE20142444A1 (es) * 2012-05-02 2015-01-09 Orexo Ab Nueva composicion de alfentanilo para el tratamiento del dolor agudo
WO2017180659A1 (en) * 2016-04-11 2017-10-19 Arizona Board Of Regents On Behalf Of University Of Arizona Opioid receptor modulators
JP7023054B2 (ja) * 2017-04-05 2022-02-21 東和薬品株式会社 レベチラセタム含有医薬組成物及びその製造方法
CN115047109B (zh) * 2022-06-17 2024-05-31 三明海关综合技术服务中心 一种检测食品中芬太尼类新精神活性物质的方法

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5785989A (en) * 1985-05-01 1998-07-28 University Utah Research Foundation Compositions and methods of manufacturing of oral dissolvable medicaments
US5288497A (en) 1985-05-01 1994-02-22 The University Of Utah Compositions of oral dissolvable medicaments
DE19758564A1 (de) 1997-11-11 1999-08-26 Gruenenthal Gmbh Formulierung einer Kombination aus Morphin und einem alpha¶2¶-adrenergem Agonisten und deren Verwendung
SE9803239D0 (sv) 1998-09-24 1998-09-24 Diabact Ab Composition for the treatment of acute pain
SE9803240D0 (sv) 1998-09-24 1998-09-24 Diabact Ab A pharmaceutical composition having a rapid action
GB9904911D0 (en) 1999-03-03 1999-04-28 Scherer Ltd R P Pharmaceutical compositions
US6264981B1 (en) 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
US20020160043A1 (en) 2001-02-27 2002-10-31 Dennis Coleman Compositions and method of manufacture for oral dissolvable dosage forms
JP4850346B2 (ja) * 2001-03-15 2012-01-11 救急薬品工業株式会社 粘膜貼付剤
US20030068356A1 (en) 2001-07-10 2003-04-10 Pather S. Indiran Sequential drug delivery systems
US20110033542A1 (en) 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
ES2270335T7 (es) 2003-01-31 2012-03-16 Orexo Ab Composicion farmaceuta de efecto.
KR20120066688A (ko) 2003-02-24 2012-06-22 파마슈티칼 프로덕션스, 인크. 경점막 약물 전달 시스템
US20050042281A1 (en) 2003-08-21 2005-02-24 Singh Nikhilesh N. Compositions for delivering therapeutic agents across the oral mucosa
EP1708685B1 (en) 2003-12-31 2011-03-09 Cima Labs Inc. Effervescent oral opiate dosage forms and methods of administering oxycodone
US20070036853A1 (en) 2003-12-31 2007-02-15 Cima Labs Inc. Generally linear effervescent oral fentanyl dosage form and methods of administering
PT1708686E (pt) 2003-12-31 2011-04-20 Cima Labs Inc Forma de dosagem de fentanil oral efervescente geralmente linear e métodos de administração
WO2005065317A2 (en) * 2003-12-31 2005-07-21 Cima Labs Inc. Effervescent oral fentanyl dosage form
FR2883179B1 (fr) 2005-03-18 2009-04-17 Ethypharm Sa Comprime enrobe
MX2007011977A (es) 2005-03-28 2007-12-07 Orexo Ab Composiciones farmaceuticas novedosas utiles en el tratamiento del dolor.
US20060281775A1 (en) * 2005-06-14 2006-12-14 Applied Pharmacy Services, Inc. Two-component pharmaceutical composition for the treatment of pain
US20070104763A1 (en) * 2005-11-10 2007-05-10 Navinta Llc Composition of fentanyl citrate oral solid transmucosal dosage form, excipient and binding material therefore, and methods of making
US8535714B2 (en) * 2006-01-06 2013-09-17 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8865743B2 (en) 2006-01-06 2014-10-21 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8202535B2 (en) 2006-01-06 2012-06-19 Acelrx Pharmaceuticals, Inc. Small-volume oral transmucosal dosage forms
US8252328B2 (en) 2006-01-06 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US20070286900A1 (en) 2006-06-09 2007-12-13 Catherine Herry Low dose tablets of opioid analgesics and preparation process
US20100233257A1 (en) 2006-06-09 2010-09-16 Ethypharm Low dose sublingual tablets of opioid analgesics and preparation process
RU2504377C2 (ru) * 2006-07-21 2014-01-20 БайоДеливери Сайенсиз Интэнэшнл, Инк. Способ трансмукозальной доставки лекарства, средство трансмукозальной доставки лекарства (варианты) и способ лечения боли
EP2101740B1 (en) * 2006-12-04 2013-11-06 Orexo AB New non-abusable pharmaceutical composition comprising opioids
EP1964564A1 (en) 2007-04-19 2008-09-03 LAB International SRL Breakthrough Pain Management
JP5632284B2 (ja) 2007-08-07 2014-11-26 エーセルアールエックス ファーマシューティカルズ， インコーポレイテッド 経口経粘膜剤形を使用する処置時の鎮静および無痛のための組成物および方法
US20090263476A1 (en) * 2008-04-16 2009-10-22 Jobdevairakkam Christopher N Composition of Rapid Disintegrating Direct Compression Buccal Tablet
US8343978B2 (en) 2008-08-04 2013-01-01 Adds Pharmaceuticals Llc Fast onset orodispersable tablets
WO2010027770A1 (en) 2008-09-04 2010-03-11 Mallinckrodt Inc. Crystalline forms of sufentanil citrate
US8945592B2 (en) 2008-11-21 2015-02-03 Acelrx Pharmaceuticals, Inc. Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same
US20100291160A1 (en) 2009-05-13 2010-11-18 Carver David R Pharmaceutical system for trans-membrane delivery
WO2010141505A1 (en) 2009-06-01 2010-12-09 Protect Pharmaceutical Corporation Abuse-resistant delivery systems
JP2009280611A (ja) * 2009-08-26 2009-12-03 Kyukyu Yakuhin Kogyo Kk 口腔内粘膜フィルム剤
US20110091544A1 (en) 2009-10-16 2011-04-21 Acelrx Pharmaceuticals, Inc. Compositions and Methods for Mild Sedation, Anxiolysis and Analgesia in the Procedural Setting
US20110262442A1 (en) 2009-11-06 2011-10-27 Adenios, Inc. Compositions for treating cns disorders
US20110150989A1 (en) 2009-12-22 2011-06-23 Mallinkckrodt Inc. Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans
PE20142444A1 (es) * 2012-05-02 2015-01-09 Orexo Ab Nueva composicion de alfentanilo para el tratamiento del dolor agudo

Also Published As

Publication number Publication date
RS57951B1 (sr) 2019-01-31
HK1203399A1 (en) 2015-10-30
HRP20181761T1 (hr) 2018-12-28
RS55489B1 (sr) 2017-04-28
TR201815935T4 (tr) 2018-11-21
US20180214437A1 (en) 2018-08-02
EA201401200A1 (ru) 2015-02-27
LT3150199T (lt) 2018-11-12
SI2849730T1 (sl) 2017-02-28
US20140005223A1 (en) 2014-01-02
AU2013255640A1 (en) 2014-11-20
EA028110B1 (ru) 2017-10-31
JP2015515974A (ja) 2015-06-04
SG11201407081PA (en) 2014-11-27
MX360665B (es) 2018-11-13
HRP20161634T1 (hr) 2017-01-13
EP2849730A1 (en) 2015-03-25
DK2849730T3 (en) 2017-02-13
KR20150005695A (ko) 2015-01-14
PE20142444A1 (es) 2015-01-09
PL3150199T3 (pl) 2019-03-29
NZ701428A (en) 2016-10-28
BR112014027213A2 (pt) 2017-06-27
CA2871805A1 (en) 2013-11-07
ES2614757T3 (es) 2017-06-01
US9345698B2 (en) 2016-05-24
EP3150199A1 (en) 2017-04-05
IL235272B (en) 2018-10-31
AU2013255640B2 (en) 2017-06-15
SMT201700086T1 (it) 2017-03-08
US20150133501A1 (en) 2015-05-14
ME02644B (me) 2017-06-20
PT2849730T (pt) 2017-02-15
CY1120820T1 (el) 2019-12-11
CN104427978A (zh) 2015-03-18
CN104427978B (zh) 2017-03-01
SI3150199T1 (sl) 2018-12-31
CO7170181A2 (es) 2015-01-28
ES2694644T3 (es) 2018-12-26
ZA201407559B (en) 2016-05-25
BR112014027213A8 (pt) 2018-01-16
EP2849730B1 (en) 2016-11-09
SMT201800585T1 (it) 2019-01-11
LT2849730T (lt) 2016-12-27
SMT201700086B (it) 2017-03-08
CY1118570T1 (el) 2017-07-12
MX2014013176A (es) 2015-01-19
US8815911B2 (en) 2014-08-26
HUE031792T2 (en) 2017-07-28
US20170071927A1 (en) 2017-03-16
PH12014502407B1 (en) 2015-01-12
JP6275696B2 (ja) 2018-02-14
PL2849730T3 (pl) 2017-05-31
IN2014MN02156A (enExample) 2015-08-28
PT3150199T (pt) 2018-11-21
US9782396B2 (en) 2017-10-10
EP3150199B1 (en) 2018-08-08
PH12014502407A1 (en) 2015-01-12
WO2013164620A1 (en) 2013-11-07
DK3150199T3 (en) 2018-11-12

Similar Documents

Publication Publication Date Title
BR112014013691A2 (pt) pré-formulação, métodos para distribuição de um agente ativo de peptídeo, para a preparação de uma composição cristalina líquida, de tratamento ou profilaxia de um sujeito, processo para a formação de uma pré-formulação, uso de uma mistura cristalina não líquida de baixa viscosidade, dispositivo de administração de pré-preenchido, e, kit
CL2014001829A1 (es) Compuestos derivados de indolizina; procedimiento de preparación; composiciones farmacéuticas que los contienen y uso en el tratamiento del cancer.
MX2015009105A (es) Composiciones en solucion solida y su uso en inflamacion cronica.
CL2013000481A1 (es) Metodo y para mejorar la eficacia y/o reducir los efectos secundarios de una farmacoterapia administrada de forma suboptima que comprende la administracion de un hexitol sustituido; composicion farmaceutica; combinacion farmaceutica; uso para tratar enfermedades proliferativas.
CL2014003444A1 (es) Compuestos derivados tienopirimidina; proceso de preparacion; composicion farmaceutica que los comprende; combinacion farmaceutica; uso en el tratamiento de canceres y enfermedades autoinmunes.
CL2012003281A1 (es) Uso de compuestos específicos estimuladores y/o activadores de sgc; formulacion farmaceutica que comprende dichos compuestos; kit que comprende los compuestos, y uso para la prevencion y/o tratamiento de la esclerosis sistematica.
CL2014002754A1 (es) Forma de dosis de liberación controlada solida que comprende un nucleo con una primera porcion de un analgesico opioide y una cubierta que encierra el nucleo y comprende una segunda porcion del analgesico opioide; metodo de preparacion; uso en el tratamiento del dolor. (divisional de solicitud n°1450-2014).
CL2013000718A1 (es) Un complejo de inclusion que comprende a) una ciclodextrina, b) fulvestrant y c) un portador; su metodo de preparacion; formulacion y forma de dosificacion que comprende al complejo; preparacion que comprende al complejo o a la formulación; y su uso en el tratamiento del cancer y lupus eritematoso sistemico, entre otras enfermedades.
CL2014000575A1 (es) Una composicion farmaceutica que comprende microparticulas de buprenorfina en mezcla asociativa con particulas que comprenden un acido debil o particulas que comprenden materiales formadores de tampon debilmente acido; procedimiento para su preparacion; y su uso para el tratamiento de la dependencia de y/o adiccion a opioides, y/o del dolor.
EP2841068B8 (en) Crhr1 antagonists for use in the treatment of patients having crh overactivity
IL285440A (en) Oral compositions containing octreotide in combination with other therapeutic agents for tretment of acromegaly
BR112015031979A2 (pt) letermovir, formulação farmacêutica oral sólida, uso de uma formulação farmacêutica oral sólida, e processo para preparar letermovir.
CL2015001652A1 (es) Compuestos derivados de 4-(bifenil-3-il)-7h-imidazo[4,5-c]piridazina, moduladores de la actividad del receptor gabaa; composicion farmaceutica que los comprende; combinacion que los comprende junto a un segundo agente farmaceuticamente activo; metodo de tratamiento del dolor; y su uso para el tratamiento del dolor.
CL2013000098A1 (es) Composicion farmaceutica que contienen una formulacion activada y potenciada de un anticuerpo para el receptor canabinoide humano; metodos de uso.
CL2014002979A1 (es) Una composicion farmaceutica para administracion sublingual que comprende una mezcla de a) microparticulas de alfentanilo, presentandose en las superficies de particulas vehiculo mas grandes, b) una base debil soluble en agua, y c) un compuesto acido debil en mezcla intima con las microparticulas de alfentanilo; su procedimiento de preparacion; y su uso para el tratamiento del dolor.
GT201200304A (es) Composiciones farmacéuticas que comprenden hidromorfona y naloxona
DOP2012000279A (es) Composiciones farmaceuticas que comprenden hidromorfona y naloxona
BR112012022243A8 (pt) Uso de um inibidor de autofagia baseado em tioxantona e de um composto indutor de autofagia para terapia de câncer, composição farmacêutica e kit farmacêutico
CL2013001250A1 (es) Composicion intravenosa que contiene ibuprofeno y paracetamol combinados en dosis definidas; y uso en el tratamiento del dolor y/o inflamacion.
CL2013000866A1 (es) Sales cristalinas oxalato y fosfato del conjugado naloxolpolietilenglicol; metodo de preparacion; composicion farmaceutica que lo comprende; y su uso para el tratamiento del dolor.
MX384877B (es) Composiciones de éster de colina de ácido lipoico y métodos de uso.
CL2014003525A1 (es) Composicion farmaceutica que comprende fimasartan, hidroclorotiazida y un aglutinante; procedimiento de preparacion; su uso en el tratamiento de hipertension.
BR112018072113A2 (pt) excipiente à base de proteínas para ingredientes farmacêuticos ativos
EA201692276A1 (ru) Комбинации тиотропия бромида, формотерола и будесонида для лечения хобл
BR112016009749A8 (pt) hidromorfona e naloxona para tratamento de dor e síndrome de disfunção intestinal opioide